What happens if I fail one component of the EPA?

You can retake individual components, but you must pass all three to achieve the qualification. There is a maximum of two retakes per component, and you must wait at least 30 days between attempts. Retakes incur additional fees, so it's important to prepare thoroughly. Your training provider can support you with targeted revision.

What kind of evidence should I include in my portfolio?

Your portfolio should contain 10-15 pieces of evidence covering all areas of the standard, such as site initiation visit reports, monitoring visit logs, safety reports, ethics submission documents, and training records. Each piece must be annotated to explain how it demonstrates your competence, with a focus on your personal contribution and decision-making.

How is the project report assessed?

The project report is assessed on its structure, depth of analysis, and relevance to clinical trial practice. You must present your findings to a panel and answer questions. The report should be around 4,000-6,000 words, excluding appendices, and include a clear introduction, methodology, results, discussion, and conclusion. The panel will probe your understanding of the regulatory and ethical implications.

Do I need to know the EU Clinical Trials Regulation for the EPA?

Yes, but primarily in the context of its impact on UK trials post-Brexit. The UK has retained the EU Clinical Trials Directive (2001/20/EC) via SI 2004/1031, but the EU Regulation (536/2014) applies to trials in the EU. You should understand the differences, especially regarding sponsorship, safety reporting, and transparency requirements. The multiple-choice test may include questions on both frameworks.

Can I use my own workplace projects for the EPA?

Absolutely. The EPA is designed to be work-based, so using real projects from your employment is encouraged. Ensure you have permission from your employer and that any confidential data is anonymised. Your project report should focus on a specific issue or improvement you led, such as implementing a new monitoring tool or streamlining the ethics submission process.

Marshall Assessment Level 6 Clinical Trials Specialist - End-Point Assessment - Core Content

Q: How long does the Marshall Assessment Level 6 Clinical Trials Specialist EPA take to complete?

The EPA typically takes 3-6 months from gateway to final result. The multiple-choice test is scheduled first, followed by the portfolio submission and professional discussion, and finally the project report presentation. You must complete all components within a 12-month period from gateway, though extensions may be granted in exceptional circumstances.

MARSHALL ASSESSMENT LIMITED

vocational

This element consolidates the essential competencies for a Clinical Trials Specialist, ensuring safe and compliant trial conduct. It covers the application of Good Clinical Practice (GCP) principles, effective protocol management, and critical evaluation of trial data to uphold patient safety and research integrity. Mastery of this content demonstrates readiness for independent specialist practice in a regulated environment.

Learning Outcomes

Assessment Guidance

Key Skills

Key Terms

Assessment Criteria

Assessment criteria

Marshall Assessment Level 6 Clinical Trials Specialist - End-Point Assessment

Topic Overview

The Marshall Assessment Level 6 Clinical Trials Specialist End-Point Assessment (EPA) is the final, synoptic evaluation for apprentices completing the Clinical Trials Specialist standard. It assesses the knowledge, skills, and behaviours required to operate as a competent specialist within clinical trial management, covering regulatory compliance, trial design, data integrity, and patient safety. This EPA is crucial because it validates that you can independently manage complex clinical trial activities, from ethics submissions to close-out, in line with Good Clinical Practice (GCP) and UK regulatory frameworks.

The assessment comprises three components: a multiple-choice test (knowledge), a portfolio-based professional discussion (skills and behaviours), and a project report with presentation and questioning (synoptic). You must pass all components to achieve the qualification. The EPA is designed to mirror real-world responsibilities, such as overseeing site initiation visits, managing adverse event reporting, and ensuring data quality. Mastery of this EPA demonstrates readiness for roles like Clinical Trial Coordinator, Clinical Research Associate, or Trial Manager within pharmaceutical, biotech, or contract research organisations.

This topic fits within the wider Applied Science curriculum as a capstone that integrates scientific principles (e.g., statistics, pharmacology) with operational and ethical considerations. It emphasises the critical path from protocol development to regulatory submission, highlighting the importance of meticulous documentation and stakeholder communication. Understanding the EPA structure and expectations is essential for effective preparation and career progression in clinical research.

Key Concepts

Core ideas you must understand for this topic

→Good Clinical Practice (GCP): The international ethical and scientific quality standard for designing, conducting, recording, and reporting clinical trials. You must know ICH GCP E6(R2) guidelines and how they apply to trial oversight, informed consent, and data integrity.
→Trial Lifecycle Management: From feasibility and site selection through initiation, monitoring, and close-out. Key activities include regulatory submissions (e.g., MHRA, REC), safety reporting (SAE/SUSAR), and data query resolution.
→Risk-Based Monitoring: A modern approach focusing resources on critical data and processes. Understand how to develop a monitoring plan, identify risks (e.g., protocol deviations, data errors), and implement mitigation strategies.
→Data Integrity and Source Data Verification (SDV): Ensuring that trial data are accurate, complete, and verifiable from source documents. This includes understanding ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, Available).
→Regulatory and Ethics Submissions: Knowledge of the UK regulatory landscape (MHRA, HRA, REC) and the timelines for approvals, amendments, and annual safety reports. Also covers the Clinical Trials Regulations (SI 2004/1031) and the EU Clinical Trials Regulation (if applicable post-Brexit).

Learning Objectives

What you need to know and understand

Evaluate the impact of regulatory frameworks on clinical trial design and conduct.
Apply risk-based monitoring techniques to ensure data quality and subject protection.
Design a corrective and preventive action (CAPA) plan for protocol deviations.
Analyze informed consent processes against ethical and legal requirements.
Demonstrate competency in managing essential documents for inspection readiness.
Critically appraise data integrity practices in clinical trial settings.

Assessment Criteria

Key criteria assessors look for in your portfolio

Award credit for demonstrating systematic application of GCP principles in case study responses.
Evidence of accurate identification and classification of protocol deviations per ICH E6(R3).
Clearly outlines a risk assessment with appropriate mitigation strategies for a mock trial scenario.
Provides a thorough root cause analysis in CAPA planning, linking to specific evidence.
Demonstrates understanding of the role of the trial master file (TMF) in inspection readiness.

Assessment Guidance

Guidance for achieving higher grades

💡Structure answers using the ICH E6(R3) framework to evidence systematic knowledge.
💡Use specific, anonymized examples from work-based practice to illustrate applied competence.
💡For scenario-based tasks, explicitly link actions to patient safety and data integrity outcomes.
💡Review the latest MHRA guidance on inspection readiness before the assessment.
💡For the professional discussion, use the STAR method (Situation, Task, Action, Result) to structure your answers. Be specific about your role and the impact of your actions. For example, describe a time you resolved a data query: what was the issue, what steps did you take, and what was the outcome?
💡In the project report, ensure your conclusion directly addresses the research question or problem you set out to solve. Use appendices for supporting documents (e.g., SOPs, data tables) but keep the main body concise. Examiners look for critical thinking, not just description.
💡For the multiple-choice test, practice with sample questions under timed conditions. Focus on areas like GCP principles, adverse event reporting timelines, and the roles of regulatory bodies. Pay attention to wording—'must', 'should', 'may' indicate different levels of requirement.

Common Mistakes

Common errors to avoid in your coursework

Confusing clinical trial monitoring with auditing, leading to misaligned objectives.
Overlooking the importance of ongoing informed consent in long-duration trials.
Failing to distinguish between minor and major protocol deviations in documentation.
Relying on generic risk assessments without tailoring to the specific protocol design.
Misconception: The portfolio is just a collection of evidence. Correction: The portfolio must demonstrate how you applied knowledge and skills in real situations. Each piece of evidence should be cross-referenced to the standard's criteria, with a reflective narrative showing your thought process and decision-making.
Misconception: The multiple-choice test is easy and doesn't require preparation. Correction: The test covers detailed regulatory knowledge, including specific timelines (e.g., 60 days for initial REC review), definitions (e.g., IMP, SAE), and GCP requirements. Many questions are scenario-based, requiring application rather than recall.
Misconception: The project report is just a summary of your work. Correction: The report must be a structured, analytical document that demonstrates your ability to critically evaluate a trial-related issue, propose solutions, and justify decisions. It should include a clear methodology, results, and discussion, with references to regulations and literature.

Frequently Asked Questions

Common questions students ask about this topic

Before You Start

Prior knowledge that will help with this topic

•Understanding of clinical trial phases (I-IV) and basic pharmacology (e.g., pharmacokinetics, pharmacodynamics).
•Familiarity with the UK healthcare system and regulatory bodies (MHRA, HRA, REC).
•Experience in a clinical trial setting, such as a Clinical Trial Administrator or Assistant role, to provide context for the EPA components.

Key Terminology

Essential terms to know

Good Clinical Practice (GCP) compliance
Protocol development and deviation management
Informed consent and patient safety
Data integrity and source documentation
Risk-based monitoring
Regulatory inspection readiness

Ready to learn?

AI-powered learning tailored to this unit

Marshall Assessment Level 6 Clinical Trials Specialist - End-Point Assessment - Core Content

Assessment criteria

Topic Overview

Key Concepts

Learning Objectives

Assessment Criteria

Assessment Guidance

Common Mistakes

Frequently Asked Questions

Before You Start

Key Terminology

Ready to learn?

Related Topics in MARSHALL ASSESSMENT LIMITED vocational Applied Science

Marshall Assessment Level 3 Laboratory Technician v1.2 - End Point Assessment - Core Content

Marshall Assessment Level 5 Technician Scientist - End Point Assessment - Core Content